Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Fiche publication
Date publication
août 2017
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A
Lien Pubmed
Résumé
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib.
Mots clés
Adult, Aged, Benzimidazoles, pharmacology, Biomarkers, Tumor, metabolism, Drug Resistance, Neoplasm, drug effects, Female, Follow-Up Studies, Gastrointestinal Neoplasms, drug therapy, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, pharmacology, Male, Middle Aged, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors, pharmacology, Quinolones, pharmacology, Salvage Therapy
Référence
Br. J. Cancer. 2017 Aug;: